Risk of recurrent venous thromboembolism in hormone therapy users;
Misclassification rates in breast histopathology biopsies: how can they be lowered?;
Menopause and work;
Cosmetics and women's health;
Endocrine-disrupting chemicals – are they of concern and can we really reduce our exposure;
NAMS Menopause Care;
HRT, dry eyes and other ocular manifestations;
Articles available to Members as well as access to the AMS journal Changes, NAMS First to Know, Congress Abstracts, AGM Minutes, Award Winners and more...
Log on to view.
- Helping to head off fractures during menopause
- Early age menstrual periods increases risk of premature and early menopause
- The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal
- Cardiovascular risk assessment in women – an update
IMS Our Menopause World
IMS Menopause Live
One of the main issues discussed in relation to postmenopausal hormone therapy (HT) is the risk for venous thromboembolic (VTE) events. In fact, this safety aspect of HT use is probably the only significant one in healthy women younger than 60 or during the first decade of use. A history of VTE usually deters physicians from prescribing HT as these women have anyway a higher risk for recurrent VTE in the future. Is this true also for women who were already using HT when the index VTE occurred? Read more...
Because misclassification of breast biopsies is relatively common, and no prior study had analyzed strategies for reducing error, the recent Elmore study is timely . Here, 12 different strategies for acquiring second opinions were compared in order to help define which strategies worked best to reduce misclassification errors. The authors systematically tested whether and which pathology classification affected the best strategic choice for: invasive breast cancer, ductal carcinoma in situ (DCIS), atypia, proliferative without atypia, or benign without atypia. Also analyzed was the influence of the perceived case difficulty, the pathologists’ clinical volumes, and local institutional policy. Read more...
Menopause is a normal life event for women and so it is not an illness or a medical condition. This often means that the symptoms of the menopause are too often under recognized, undervalued and not taken seriously. The psychological symptoms associated with the menopause such as loss of self-confidence, low self-esteem, anxiety and depressive symptoms are the ones that often affect women the most.
On average, women spend nearly one-third of their life being postmenopausal. The retirement age is increasing and elderly people are far more active, both physically and mentally, than they were in the past. Symptoms of the menopause last far longer than most women anticipate; the average length of time is 4 years and many women still have some symptoms for longer than 10 years. Read more...
Cosmetics. Everyone uses them, women and men alike. Cosmetics include many different materials with various roles that determine the activity, texture, color and smell of the final product. People are not aware of the fact that, unlike medications, cosmetics are not tested as rigorously by the regulatory authorities and the included chemicals may be harmful. The external placement and targets for use should not distract us from investigating potential systemic ill-effects. For example, ingredients in cosmetics may have an effect on a variety of hormonal pathways. A recent review, which analyzed possible associations with age at menopause, concluded that there is lack of data on the relevant risk outcomes of cosmetic use . Read more...
From time to time, we have to remind ourselves and the health-care providers that estrogen and the other sex steroids are actually involved in all the body organs, and that their physiological effects are not limited to fertility, treatment of menopausal symptoms, or cardiovascular and bone protection. Menopause Live has addressed in the past the effects of estrogen on other tissues and bodily functions, such as the skin, the voice or hearing. This time, I put the eye and sight into this context. A small, but double-blind, placebo-controlled study (n = 40, age 63.9 ± 5.1 years, 13.2 ± 6.3 years postmenopause) investigated the outcomes of estrogen, testosterone or their combination in hysterectomized women with dry eyes . The results demonstrated estrogen-related worsening in dryness intensity after 8 weeks of estradiol gel 1 mg/g as compared to placebo; 1% testosterone cream showed a neutral effect, but a combination of the two hormones led to a significant increase in tear secretion. Read more...
Have you noticed the increased number of publications on natural remedies for menopause symptoms in good-quality journals? The reason for these studies, in my view, is not only the alleged problematic benefit–risk balance of hormone therapy (HT) or other approved medications, but the higher awareness of women to achieve better quality of life during midlife and beyond. This may be more prominent in developing countries where traditional medicine is popular, but is certainly valid in the Western world too. The willingness of Editors of journals with a medium to high impact factor to accept such papers, provided that these meet the quality standards of the aforementioned journals, gives a tail wind to this trend. Here are a few such examples. Read more...
Content Updated January 2017